Your browser is no longer supported. Please, upgrade your browser.
RCKT Rocket Pharmaceuticals, Inc. daily Stock Chart
Rocket Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.60 Insider Own2.10% Shs Outstand54.88M Perf Week0.22%
Market Cap1.13B Forward P/E- EPS next Y-1.94 Insider Trans0.10% Shs Float50.18M Perf Month22.76%
Income-82.50M PEG- EPS next Q-0.51 Inst Own98.00% Short Float16.52% Perf Quarter42.32%
Sales- P/S- EPS this Y16.70% Inst Trans3.50% Short Ratio18.46 Perf Half Y-8.61%
Book/sh5.21 P/B4.34 EPS next Y1.50% ROA-24.40% Target Price36.00 Perf Year70.57%
Cash/sh5.50 P/C4.11 EPS next 5Y10.80% ROE-30.70% 52W Range9.01 - 27.59 Perf YTD-0.70%
Dividend- P/FCF- EPS past 5Y14.60% ROI- 52W High-18.09% Beta2.12
Dividend %- Quick Ratio13.30 Sales past 5Y- Gross Margin- 52W Low150.83% ATR1.63
Employees72 Current Ratio13.30 Sales Q/Q- Oper. Margin- RSI (14)57.69 Volatility8.82% 7.93%
OptionableYes Debt/Eq0.23 EPS Q/Q-4.20% Profit Margin- Rel Volume0.91 Prev Close23.68
ShortableYes LT Debt/Eq0.23 Earnings- Payout- Avg Volume449.11K Price22.60
Recom1.50 SMA207.20% SMA5016.62% SMA20024.64% Volume406,859 Change-4.56%
Jul-02-20Initiated JP Morgan Overweight
Jun-25-20Resumed BofA/Merrill Buy $34
Jun-01-20Resumed Oppenheimer Outperform
Nov-06-19Initiated Chardan Capital Markets Buy $30
Sep-26-19Initiated Piper Jaffray Overweight
Apr-23-19Initiated Robert W. Baird Outperform
Mar-15-19Initiated BofA/Merrill Buy $27
Feb-05-19Initiated Oppenheimer Outperform $39
Sep-13-18Initiated Ladenburg Thalmann Buy $30
Jul-10-18Initiated William Blair Outperform
Jul-08-20 12:53PM  
Jun-29-20 07:00AM  
Jun-27-20 03:16PM  
Jun-08-20 07:00AM  
May-26-20 07:00AM  
May-12-20 07:00AM  
May-10-20 10:39PM  
May-06-20 07:00AM  
May-05-20 07:00AM  
Apr-22-20 07:00AM  
Apr-09-20 08:22AM  
Apr-02-20 09:00AM  
Mar-27-20 10:04AM  
Mar-19-20 07:00AM  
Mar-05-20 07:00AM  
Feb-24-20 07:00AM  
Feb-18-20 07:00AM  
Feb-11-20 09:15AM  
Feb-06-20 07:00AM  
Jan-09-20 09:44AM  
Jan-06-20 12:00PM  
Dec-29-19 03:24AM  
Dec-16-19 07:00AM  
Dec-13-19 04:01PM  
Dec-11-19 07:21AM  
Dec-10-19 10:45PM  
Dec-09-19 07:00AM  
Dec-08-19 06:00PM  
Dec-06-19 07:00AM  
Dec-05-19 07:00AM  
Dec-04-19 09:27AM  
Nov-27-19 07:00AM  
Nov-07-19 07:00AM  
Nov-06-19 09:00AM  
Nov-05-19 07:00AM  
Nov-01-19 11:16AM  
Oct-24-19 07:00AM  
Oct-22-19 07:00AM  
Oct-15-19 07:00AM  
Oct-01-19 07:00AM  
Sep-23-19 07:00AM  
Sep-10-19 07:00AM  
Sep-04-19 07:00AM  
Aug-28-19 07:00AM  
Aug-22-19 07:00AM  
Aug-07-19 07:00AM  
Jul-31-19 07:00AM  
Jun-25-19 09:24PM  
Jun-18-19 07:00AM  
May-29-19 10:00AM  
May-23-19 03:00PM  
May-09-19 01:54PM  
May-08-19 07:13AM  
May-07-19 07:00AM  
May-02-19 07:00AM  
Apr-30-19 07:00AM  
Apr-18-19 11:20AM  
Apr-16-19 08:10AM  
Apr-15-19 10:36PM  
Mar-15-19 08:00AM  
Mar-12-19 07:22AM  
Mar-11-19 07:00AM  
Mar-07-19 07:00AM  
Mar-05-19 07:00AM  
Feb-28-19 08:00AM  
Feb-26-19 07:00AM  
Feb-20-19 07:00AM  
Jan-22-19 07:00AM  
Dec-21-18 07:00AM  
Nov-30-18 12:00PM  
Nov-28-18 01:05PM  
Nov-27-18 08:02PM  
Nov-26-18 04:15PM  
Nov-25-18 04:00PM  
Nov-19-18 07:00AM  
Nov-07-18 07:01AM  
Nov-01-18 09:08AM  
Oct-19-18 07:00AM  
Oct-18-18 07:00AM  
Sep-25-18 07:00AM  
Aug-30-18 07:00AM  
Aug-08-18 07:32AM  
Jun-22-18 07:00AM  
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction, and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. It also has additional infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shah GauravPresident & CEOMar 24Option Exercise0.4390,92539,0981,061,642Mar 26 07:48 PM
Patel KinnariChief Operating OfficerMar 18Buy9.501,0009,5006,675Mar 19 07:56 PM
Shah GauravPresident & CEOFeb 25Option Exercise0.43290,000125,628976,950Feb 27 05:36 PM
RTW INVESTMENTS, LPDirectorDec 10Buy22.25225,0005,006,25017,282,324Dec 12 03:43 PM